TrialBMC medicine2026

Neoadjuvant camrelizumab combined with radiotherapy as a chemotherapy-sparing approach for resectable locally advanced esophageal squamous cell carcinoma: a phase II clinical trial (ESOCORT-NIRT).

Maohui Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.